StreetInsider.com News Articles

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932237.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.

Fri, 14 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260814/26932237.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Bellevue Group AG

Fri, 14 Aug 2026 11:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26927476.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Bellevue Group AG

Fri, 14 Aug 2026 11:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26927476.html

Jade Biosciences (JBIO) Misses Q2 EPS by 11c

Mon, 10 Aug 2026 16:15:26 -0400

Jade Biosciences (NASDAQ: JBIO) reported Q2 EPS of ($0.76), $0.11 worse than the analyst estimate of ($0.65).

For earnings history and earnings-related data on Jade Biosciences (JBIO) click here.

Jade Biosciences (JBIO) PT Raised to $47 at Wedbush

Mon, 10 Aug 2026 11:46:07 -0400

Wedbush analyst Laura Chico raised the price target on Jade Biosciences (NASDAQ: JBIO) to $47.00 (from $45.00) while maintaining a Outperform rating.

The analyst comments "Remain Outperform rated on JBIO, new $47 target. Most important in the 2Q26 update, all development timelines remain on track. Recent Otsuka (not covered) data provides important validation and read through to JADE101 in that it shows APRIL inhibition stabilizes kidney function in IgAN patients. With JADE101 showing greater potency and longer dosing intervals versus Voyxact, we like the potential for JADE101 to differentiate. No changes to our JADE101 estimates. Elsewhere in the pipeline, JBIO disclosed

Jade Biosciences (JBIO) PT Raised to $47 at Wedbush

Mon, 10 Aug 2026 11:46:07 -0400

Wedbush analyst Laura Chico raised the price target on Jade Biosciences (NASDAQ: JBIO) to $47.00 (from $45.00) while maintaining a Outperform rating.

Form 10-Q Jade Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 07:22:00 -0400

si-local-file:///var/storage/secattach/20260810/26894304.html

Form 10-Q Jade Biosciences, Inc. For: Jun 30

Mon, 10 Aug 2026 07:22:00 -0400

si-local-file:///var/storage/secattach/20260810/26894304.html

Form 8-K Jade Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260810/26894245.html

Form 8-K Jade Biosciences, Inc. For: Aug 10

Mon, 10 Aug 2026 07:14:00 -0400

si-local-file:///var/storage/secattach/20260810/26894245.html

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy
Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027
Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027
Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027
JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Mon, 10 Aug 2026 07:00:00 -0400

Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy

Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027

Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027

Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027

JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of

Voyxact 24-month data shows kidney function improvement in IgAN, BTIG comments

Tue, 04 Aug 2026 13:41:27 -0400

Investing.com -- BTIG analysts reviewed 24-month data from the VISIONARY trial for Voyxact (sibeprenlimab) in IgA nephropathy, showing continued positive changes in estimated glomerular filtration rate through the two-year mark.
The drug demonstrated an annualized eGFR slope of +0.3 mL/min/1.73 m² per year, with a 95% confidence interval ranging from -0.4 to +0.9. This result met the KDIGO therapeutic goal of limiting progressive kidney function decline to less than 1 mL/min/1.73 m² per year.
Voyxact-treated patients showed an annualized estimated eGFR slope improvement of +0.3 mL/min/1.73m²/yr compared to -4.2 mL/min/1.73m²/yr for placebo, representing a treatment effect of +4.5 mL/min/1.73m²/yr. The difference reached

Voyxact 24-month data shows kidney function improvement in IgAN, BTIG comments

Tue, 04 Aug 2026 13:41:27 -0400

Investing.com -- BTIG analysts reviewed 24-month data from the VISIONARY trial for Voyxact (sibeprenlimab) in IgA nephropathy, showing continued positive changes in estimated glomerular filtration rate through the two-year mark.
The drug demonstrated an annualized eGFR slope of +0.3 mL/min/1.73 m² per year, with a 95% confidence interval ranging from -0.4 to +0.9. This result met the KDIGO therapeutic goal of limiting progressive kidney function decline to less than 1 mL/min/1.73 m² per year.
Voyxact-treated patients showed an annualized estimated eGFR slope improvement of +0.3 mL/min/1.73m²/yr compared to -4.2 mL/min/1.73m²/yr for placebo, representing a treatment effect of +4.5 mL/min/1.73m²/yr. The difference reached

Form SCHEDULE 13G Jade Biosciences, Inc. Filed by: Paradigm Biocapital Advisors LP

Fri, 17 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260717/26784362.html

Form SCHEDULE 13G Jade Biosciences, Inc. Filed by: Paradigm Biocapital Advisors LP

Fri, 17 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260717/26784362.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Janus Henderson Group Ltd.

Wed, 08 Jul 2026 17:44:00 -0400
si-local-file:///var/storage/secattach/20260708/26748492.html

Form SCHEDULE 13G/A Jade Biosciences, Inc. Filed by: Janus Henderson Group Ltd.

Wed, 08 Jul 2026 17:44:00 -0400
si-local-file:///var/storage/secattach/20260708/26748492.html